Table 2.

Relationships between clinicopathological characteristics and PD-L1 expression in tumor cells

Clinicopathological characteristics	Overall	PD-L1 (+)	PD-L1 (−)	Odds ratio (95% CI)	Global P
	378	113(29.9%)	265(70.1%)
Age at diagnosis				1.563(1.003–2.438)	0.049
≥ 60 years	188	65(34.6%)	123(65.4%)
< 60 years	190	48(25.3%)	142(74.7%)
Gender				0.800(0.461–1.386)	0.425
Male	307	89(29.0%)	218(71.0%)
Female	71	24(33.8%)	47(66.2%)
Tumor differentiation
Well	85	21(24.7%)	64(75.3%)	1
Moderate	190	51(26.8%)	139(73.2%)	1.118(0.621–2.013)	0.710
Poor	91	38(41.8%)	53(58.2%)	2.185(1.146–4.166)	0.018
Basaloid	12	3(25.0%)	9(75.0%)	1.016(0.251–4.105)	0.982
Location
Upper thoracic	61	18(29.5%)	43(70.5%)	1
Middle thoracic	209	59(28.2%)	150(71.8%)	0.940(0.502–1.759)	0.846
Lower thoracic	108	36(33.3%)	72(66.7%)	1.194(0.605–2.358)	0.609
PT status				1.821(1.068–3.106)	0.028
pT2	103	22(21.4%)	81(78.6%)
pT3-4a	275	91(33.1%)	184(66.9%)
PN status				1.541(1.210–1.963)	< 0.001
pN0	189	40(21.2%)	149(78.8%)
pN1	116	43(37.1%)	73(62.9%)
pN2	52	20(38.5%)	32(61.5%)
pN3	21	10(47.6%)	11(52.4%)
Vascular invasion				1.025(0.656–1.600)	0.915
No	219	65(29.7%)	154(70.3%)
Yes	159	48(30.2%)	111(69.8%)
Perineural invasion				0.823(0.512–1.324)	0.422
No	253	79(31.2%)	174(68.8%)
Yes	125	34(27.2%)	91(72.8%)
Metachronous hematogenous metastasis				2.030(1.171–3.520)	0.012
No	313	85(27.2%)	228(72.8%)
Yes	65	28(43.1%)	37(56.9%)